Royalty Report: Drugs, Ophthalmological, Therapeutic – Collection: 27869


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Ophthalmological
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 27869

License Grant
A U.S. pharmaceutical announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with another U.S. pharmaceutical company which revises terms related to the Prolacria™ (diquafosol tetrasodium ophthalmic solution) 2% development program and Licensor's right to receive revenues from licensee based on net sales of Restasis® (cyclosporine ophthalmic emulsion) 0.05% and any other human ophthalmic formulations of cyclosporine owned or controlled by Licensee.
License Property
Under the amended agreement, which now runs through December 31, 2020, Licensor is entitled to receive revenues at one global rate based on net sales of Restasis® and any other human ophthalmic formulation of cyclosporine owned or controlled by licensee, with no requirement to co-promote Restasis®. The royalty rate for Restasis® in the United States remains unchanged for 2010. The annual global rate steps down from the 2010 U.S. rate by agreed upon amounts.  

Under the amended agreement, Licensor now has unilateral control over any future Prolacriaâ„¢ development and commercialization. In the event licensee resumes the Prolacriaâ„¢ clinical development program and receives regulatory approval for a Prolacriaâ„¢ product in a particular country, it will have the option to offer Prolacriaâ„¢.

Note that the actual royalty rate is from a press report and this is included at the end of the exhibit.

Field of Use
The drug is to be used for dry eyes.

IPSCIO Record ID: 26243

License Grant
The Licensor develops prescription pharmaceutical products for ophthalmic and pulmonary diseases.
License Property
The product is Restasis® for dry eye.
Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 25218

License Grant
Parties entered into a license agreement, under which Licensor licensed to Licensee exclusive development and commercialization rights, under Licensor’s AzaSite™ patent rights and certain know-how, for topical anti-infective products containing azithromycin as the sole active ingredient for human ocular or ophthalmic indications (each a “Subject Product”) in the United States and Canada and their respective territories (the “Territory”).
License Property
AzaSite (azithromycin ophthalmic solution) is a 1% sterile aqueous topical ophthalmic solution of azithromycin formulated in DuraSite® (polycarbophil, edetate disodium, sodium chloride).
Field of Use
AzaSite is an eye ointment containing azithromycin, a macrolide antibiotic that fights bacteria. Azithromycin is used to treat eye infections caused by bacteria;  bacterial conjunctivitis; commonly referred to as pink eye. AzaSite may also be used for purposes not listed in this medication guide.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.